Together, our results indicate that subset of tuft cells exhibit notable associations with severe COVID‐19, and critical drug targets, including IL10RB, ICAM1, and VIPR2, are prioritized for treating severe COVID‐19 and concomitant intestinal symptoms. Here, ICAM1 is linked to COVID-19.